Marshall Wace
SLDB icon

Marshall Wace’s Solid Biosciences SLDB Stock Holding History

Marshall Wace’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-336,325
Closed -$1.24M – 3124
2025
Q1 		$1.24M Buy
336,325
+154,824
+85% +$663K ﹤0.01% 1687
2024
Q4 		$726K Sell
181,501
-5,869
-3% -$32.2K ﹤0.01% 1883
2024
Q3 		$1.31M Sell
187,370
-86,635
-32% -$703K ﹤0.01% 1537
2024
Q2 		$1.55M Buy
+274,005
New +$2.45M ﹤0.01% 1481
2021
Q4 		– Sell
-11,179
Closed -$401K – 4256
2021
Q3 		$401K Sell
11,179
-27,883
-71% -$1.18M ﹤0.01% 2505
2021
Q2 		$2.14M Buy
39,062
+1,618
+4% +$107K 0.01% 1378
2021
Q1 		$3.11M Buy
+37,444
New +$4.14M 0.01% 1092
2019
Q2 		– Sell
-4,654
Closed -$642K – 1794
2019
Q1 		$642K Buy
4,654
+3,227
+226% +$808K 0.01% 1066
2018
Q4 		$574K Buy
+1,427
New +$671K 0.01% 1058

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Marshall Wace's SLDB Position: Q2 2025 in Review

Marshall Wace sold out of Solid Biosciences (SLDB) in Q2 2025, closing a stake of 336,325 shares — an estimated $1.24M sold.

Marshall Wace first reported a position in SLDB in Q4 2018 and held it in 9 quarters. The position peaked at $3.11M in Q1 2021. 114 funds tracked by Wall St. Rank hold SLDB as of Q2 2025.

  • Marshall Wace reported no remaining Solid Biosciences position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 336,325 Solid Biosciences shares in Q2 2025, an estimated $1.24M.
  • Marshall Wace first reported a position in Solid Biosciences in Q4 2018 and held it in 9 quarters.
  • Marshall Wace's Solid Biosciences position peaked at $3.11M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.